Overview
Erlocip 100 mg contains Erlotinib, a targeted cancer therapy that belongs to the class of tyrosine kinase inhibitors (TKIs). It is primarily used in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer, particularly in patients with specific EGFR (epidermal growth factor receptor) mutations. Erlotinib works by blocking signals that promote cancer cell growth and division, thereby slowing or stopping tumor progression.





